| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | selpercatinib (Retsevmo®) |
| Formulation | 40mg and 80mg hard capsules |
| Reference number | 4399 |
| Indication | Monotherapy for the treatment of adults advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/01/2021 |
| NICE guidance | TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer |